Maravai LifeSciences Holdings, Inc. (MRVI)
| Market Cap | 9.27B |
| Revenue (ttm) | 221.71M |
| Net Income (ttm) | 58.37M |
| Shares Out | 267.84M |
| EPS (ttm) | 0.22 |
| PE Ratio | 167.35 |
| Forward PE | 56.82 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $36.47 |
| Previous Close | $32.52 |
| Change ($) | 3.95 |
| Change (%) | 12.15% |
| Day's Open | 34.77 |
| Day's Range | 33.49 - 36.87 |
| Day's Volume | 1,226,974 |
| 52-Week Range | 23.62 - 37.79 |
SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is sched...
Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences , Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators...
Stocks Rebound; Qualcomm, Maravai, One Medical Clear Buy Points
Stocks rebound, Qualcomm, Maravai, One Medical clear buy points. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, st...
SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators,...
Maravai LifeSciences has received a welcome public debut. The company provides a crucial role in drug development and in fact even in the Pfizer/BioNTech vaccine.
SAN DIEGO, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and bi...
Maravai Life Sciences Holdings (NASDAQ:MRVI) will hit the public markets with perfect timing as it sees its mRNA product used by COVID-19 vaccine makers. The Offering: Maravai Life Sciences pl...
About MRVI
Maravai LifeSciences Holdings operates as a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in thr... [Read more...]
| Industry Biotechnology | IPO Date Nov 20, 2020 |
| CEO Carl W. Hull | Employees 390 |
| Stock Exchange NASDAQ | Ticker Symbol MRVI |
Financial Performance
In 2019, MRVI's revenue was $143.14 million, an increase of 15.59% compared to the previous year's $123.83 million. Losses were -$4.47 million, -0.04% less than in 2018.
Analyst Forecasts
According to 10 analysts, the average rating for MRVI stock is "Strong Buy." The 12-month stock price forecast is 33.67, which is a decrease of -7.68% from the latest price.